What Is Sermorelin? Research Evidence & Profile

What Is Sermorelin Acetate?

Sermorelin Acetate is a peptide entry associated with growth-hormone-releasing hormone research contexts. This page identifies the material as Growth Hormone-Releasing Hormone Analog (Sermorelin Acetate), with amino acid count 29; synonyms Sermorelin Acetate. The Sermorelin Acetate identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

12ClinicalTrials.gov query records

14PubMed query records

6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Sermorelin Acetate is organized around growth-hormone-releasing hormone research, peptide signaling studies, ligand-response analysis, and analytical peptide workflows. For Sermorelin Acetate, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
NCT03375788Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk	Phase 2	Completed	Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat, Fatty Liver	2025-11-20
NCT07481734Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)	Phase 2	Recruiting	Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis	2026-03-19
NCT02012556Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients	Phase 1	Completed	HIV	2013-12-16
NCT06554717Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV	Phase 2	Recruiting	HIV-1-infection, Frailty, Impaired Physical Function, Abdominal Obesity, Aging	2026-05-19
NCT01632592Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue	NA	Withdrawn	Abdominal Obesity	2014-01-24
NCT03226821Body Composition and Adipose Tissue in HIV	Phase 4	Terminated	HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition	2026-05-19

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Response to a growth hormone-releasing hormone analog in heifers treated with recombinant growth hormone.

Domestic animal endocrinology · 1988 Jan

PMID 3147164

Selected PubMed record

Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.

The Journal of clinical endocrinology and metabolism · 2011 Jan

PMID 20943777

Selected PubMed record

Metabolic dysfunction-associated steatotic liver disease in people with HIV.

Current opinion in HIV and AIDS · 2025 Jul 1

PMID 40397552

Selected PubMed record

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.

HIV/AIDS (Auckland, N.Z.) · 2011

PMID 22096409

Selected PubMed record

Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.

International journal of oncology · 2005 Jun

PMID 15870879

Selected PubMed record

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

JCI insight · 2020 Aug 20

PMID 32701508

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: Growth Hormone-Releasing Hormone Analog (Sermorelin Acetate)
Available Specifications: 2mg, 5mg, 10mg
Pack Format: 10 Vials
CAS Number: 86168-78-7
Molecular Formula: C149H246N44O42S
Molecular Weight: 3357.9 g/mol
Amino Acid Count: 29
Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 (GRF 1-29 NH2)
Synonyms: Sermorelin Acetate
Physical Form: Lyophilized powder
Salt / Counter-Ion Form: Acetate form is explicit in the catalogue name; the counter-ion ratio is not inferred beyond that label.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 16132413 · Product form must still be matched to the catalogue and batch record.

Research Tools for Sermorelin Acetate

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Sermorelin Acetate Research Summary

Identity

Growth Hormone-Releasing Hormone Analog (Sermorelin Acetate); specifications: 2mg, 5mg, 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

Evidence

12 registry records and 14 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Sermorelin Acetate is represented here by the catalogue identity Growth Hormone-Releasing Hormone Analog (Sermorelin Acetate). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 2mg, 5mg, 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Sermorelin Acetate is organized around growth-hormone-releasing hormone research, peptide signaling studies, ligand-response analysis, and analytical peptide workflows. For Sermorelin Acetate, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 12 ClinicalTrials.gov records and 14 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Sermorelin Acetate FAQ

What is Sermorelin Acetate?

What research records are indexed for Sermorelin Acetate?

The synchronized query returned 12 ClinicalTrials.gov records and 14 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Sermorelin Acetate FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.